Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Winemaker Chapel Down appoints new chair, delivers confident outlook

(Sharecast News) - English winemaker Chapel Down has announced the departure of its chair Martin Glenn after five years at the helm as it reported results for the first half and delivered a confident outlook. Glenn has stepped down as chair and director of the board, effective immediately, the company said, with board member Michael Spencer appointed as his replacement.

Spencer, who is the founder of financial firms ICAP and NEX, has been on the board of the winemaker since 2023.

"With his exceptional track record in shareholder value creation and deep understanding of our business, Chapel Down will be in very capable hands," Glenn said in a statement.

The appointment came as the company delivered a confident outlook for the rest of 2025, with this year's warm summer providing ideal growing conditions and resulting in a "high-quality vintage at an above-average yield".

Since its last shareholder update in July, trading has remained robust, especially in the off-trade channel, the company said.

Net sales revenues over the six months to 30 June were up 11% at £7.93m. However, a drop in the gross margin to 46.1% from 48.0% and a lower fair value adjustment to biological produce (£0.2m compared with the £0.8m recorded last year), resulted in adjusted EBITDA sinking 23% to £1.23m.

On a reported basis, the company registered a loss before tax of £0.69m, compared with a profit of £0.04m the year before.

However, Chapel Down said: "The board remains confident in achieving market expectations for 2025 FY, thereby delivering strong sales growth and a return to full profitability."

Shares were up 7.1% at 45p by 1000 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.